ImmunoGen, Inc., a company involved in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, has entered into an exclusive collaboration with Takeda Pharmaceutical Co. to develop and commercialize ELAHERE (mirvetuximab soravtansine-gynx) in Japan.

ImmunoGen will receive a one-time, upfront payment and an additional payment upon conversion of U.S. FDA accelerated approval of ELAHERE in platinum-resistant ovarian cancer (PROC) to full approval. The company is eligible to receive additional payments if Takeda achieves prespecified regulatory and commercial milestones, as well as royalties on future sales of ELAHERE in Japan.

Per the agreement, ImmunoGen has retained exclusive production rights and will supply product for development and commercial use in Japan. In exchange, Takeda will receive an exclusive license to develop and commercialize ELAHERE in Japan and is responsible for all regulatory filings and obligations.

“As a leader in the development and commercialization of novel products in oncology for more than two decades and with a deep heritage and presence in Japan, Takeda is the ideal partner to help us deliver ELAHERE to eligible patients in this important market,” said Mark Enyedy, ImmunoGen’s President, and CEO. “Building upon our strong commercial launch in the US, this partnership reinforces the continued excitement around ELAHERE’s practice-changing potential and our commitment to bringing this biomarker-directed ADC to patients globally.”

Teresa Bitetti, president of the global oncology business unit at Takeda said, “We are pleased to bring ELAHERE to Japan, where there is a significant unmet need for patients with ovarian cancer, particularly for those whose disease has become resistant to platinum-based treatments. The data from the Phase 3 MIRASOL study demonstrate the potential for ELAHERE to become the new standard of care for this devastating disease, and we are confident this collaboration with ImmunoGen will bring significant value to patients in Japan.”